Joel Greenblatt Gotham Asset Management
Joel Greenblatt is a co-founder of Gotham Asset Management and a well-known value investor, professor, and author. He gained wide recognition for The Little Book That Beats the Market and for popularizing a systematic value approach often called the “magic formula.” Greenblatt’s career spans special-situation investing, quantitative value strategies, and investor education.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$82.2M |
| 2 |
Conagra Brands
CAG
|
+$63.5M |
| 3 |
Intuit
INTU
|
+$53.2M |
| 4 |
PARA
Paramount Global Class B
PARA
|
+$51.9M |
| 5 |
CVS Health
CVS
|
+$43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Texas Instruments
TXN
|
+$40.5M |
| 2 |
Merck
MRK
|
+$39.5M |
| 3 |
DD
Du Pont De Nemours E I
DD
|
+$38.8M |
| 4 |
Viatris
VTRS
|
+$38.8M |
| 5 |
DaVita
DVA
|
+$37.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.31% |
| 2 | Industrials | 19.34% |
| 3 | Healthcare | 18.39% |
| 4 | Consumer Discretionary | 16.87% |
| 5 | Consumer Staples | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$32B
| $89M | 1.07% |
368,095
+69,422
| +23% | +$18.3M |
|
2
Gilead Sciences
GILD
$181B
| $84.8M | 1.02% |
1,016,142
+48,500
| +5% | +$4.3M |
|
|
TFCFA
3
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $76.3M | 0.92% |
+2,822,168
| New | +$82.2M |
|
4
Apple
AAPL
$4.51T
| $74.5M | 0.89% |
3,116,644
+214,688
| +7% | +$5.34M |
|
5
Amgen
AMGN
$238B
| $73.9M | 0.89% |
485,933
+162,528
| +50% | +$25.3M |
|
|
ESRX
6
DELISTED
Express Scripts Holding Company
ESRX
| $73M | 0.88% |
962,979
-195,449
| -17% | -$14.4M |
|
7
HCA Healthcare
HCA
$92.9B
| $70.6M | 0.85% |
916,670
+294,438
| +47% | +$23.2M |
|
|
PARA
8
DELISTED
Paramount Global Class B
PARA
| $70.1M | 0.84% |
1,287,175
+954,696
| +287% | +$51.9M |
|
9
eBay
EBAY
$46.3B
| $69.9M | 0.84% |
2,986,196
+142,010
| +5% | +$3.43M |
|
10
RTX Corp
RTX
$283B
| $69.2M | 0.83% |
1,072,961
-292,440
| -21% | -$18.7M |
|
11
Pfizer
PFE
$160B
| $68.2M | 0.82% |
2,042,949
+380,514
| +23% | +$12.1M |
|
12
J.M. Smucker
SJM
$13.3B
| $67.7M | 0.81% |
444,505
+100,643
| +29% | +$13.4M |
|
|
13
Conagra Brands
CAG
$7.89B
| $66.3M | 0.8% |
+1,782,336
| New | +$63.5M |
|
14
Oracle
ORCL
$422B
| $62.9M | 0.75% |
1,537,195
+974,639
| +173% | +$38.9M |
|
|
15
CVS Health
CVS
$119B
| $62.4M | 0.75% |
652,002
+431,750
| +196% | +$43M |
|
16
Cisco
CSCO
$438B
| $61.7M | 0.74% |
2,151,741
+330,747
| +18% | +$9.28M |
|
17
Zimmer Biomet
ZBH
$19.3B
| $61.3M | 0.73% |
524,097
+372,168
| +245% | +$42.1M |
|
18
Cardinal Health
CAH
$53.4B
| $59.9M | 0.72% |
768,372
+529,878
| +222% | +$42.2M |
|
19
Qualcomm
QCOM
$169B
| $59.9M | 0.72% |
1,118,317
+40,798
| +4% | +$2.15M |
|
|
20
Intuit
INTU
$100B
| $56.8M | 0.68% |
+508,586
| New | +$53.2M |
|
21
AbbVie
ABBV
$468B
| $56.1M | 0.67% |
905,598
+259,763
| +40% | +$15.8M |
|
22
Emerson Electric
EMR
$87.7B
| $55.2M | 0.66% |
1,057,481
+403,682
| +62% | +$21.4M |
|
23
Boeing
BA
$169B
| $54.5M | 0.65% |
419,452
-131,762
| -24% | -$17.2M |
|
24
Target
TGT
$75.1B
| $54.3M | 0.65% |
777,449
+388,316
| +100% | +$29M |
|
|
IM
25
DELISTED
Ingram Micro
IM
| $53.1M | 0.64% |
1,525,456
+15,788
| +1% | +$550K |
|
Similar funds
Joel Greenblatt's Q2 2016 Portfolio in Review
As of Q2 2016, Joel Greenblatt held 1,194 positions worth $8.34B, down 6.5% from $8.92B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Joel Greenblatt withdrew a net $527M in Q2 2016, closing 260 positions and reducing 357 holdings. Its most notable exit was Viatris, an estimated $38.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Joel Greenblatt opened a new position in Twenty-First Century Fox, Inc. Class A worth $76.3M.
- Joel Greenblatt's largest Q2 2016 buy was Twenty-First Century Fox, Inc. Class A: 2,822,168 shares worth $76.3M.
- Joel Greenblatt added most to Paramount Global Class B in Q2 2016, an estimated $51.9M increase.
- Joel Greenblatt's biggest Q2 2016 reduction was Texas Instruments, cutting an estimated $40.5M.
- Joel Greenblatt fully exited Viatris in Q2 2016, selling an estimated $38.8M.
- Joel Greenblatt's ten largest holdings make up 9% of its $8.34B portfolio in Q2 2016.
- Joel Greenblatt opened 244 new positions and closed 260 in Q2 2016.
- Joel Greenblatt's portfolio value fell 6.5% quarter-over-quarter to $8.34B.
Based on Gotham Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.